JP2022523074A5 - - Google Patents
Info
- Publication number
- JP2022523074A5 JP2022523074A5 JP2021544152A JP2021544152A JP2022523074A5 JP 2022523074 A5 JP2022523074 A5 JP 2022523074A5 JP 2021544152 A JP2021544152 A JP 2021544152A JP 2021544152 A JP2021544152 A JP 2021544152A JP 2022523074 A5 JP2022523074 A5 JP 2022523074A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- composition according
- melanoma
- cell carcinoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962798406P | 2019-01-29 | 2019-01-29 | |
| US62/798,406 | 2019-01-29 | ||
| US201962881275P | 2019-07-31 | 2019-07-31 | |
| US62/881,275 | 2019-07-31 | ||
| US201962938415P | 2019-11-21 | 2019-11-21 | |
| US62/938,415 | 2019-11-21 | ||
| PCT/US2020/015723 WO2020160180A1 (en) | 2019-01-29 | 2020-01-29 | Compounds and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022523074A JP2022523074A (ja) | 2022-04-21 |
| JP2022523074A5 true JP2022523074A5 (enExample) | 2023-02-07 |
| JP7665518B2 JP7665518B2 (ja) | 2025-04-21 |
Family
ID=71841237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021544152A Active JP7665518B2 (ja) | 2019-01-29 | 2020-01-29 | 化合物及びその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230079819A1 (enExample) |
| EP (1) | EP3917527B1 (enExample) |
| JP (1) | JP7665518B2 (enExample) |
| CN (1) | CN113645971B (enExample) |
| AU (1) | AU2020214308A1 (enExample) |
| ES (1) | ES3032327T3 (enExample) |
| IL (1) | IL285177B2 (enExample) |
| WO (1) | WO2020160180A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017087885A1 (en) | 2015-11-19 | 2017-05-26 | Dana-Farber Cancer Institute, Inc. | Methods of identifying compounds that interfere with erg-driven misguidance of baf complexes in tmprss2-erg driven prostate cancers |
| US11497752B2 (en) | 2018-01-30 | 2022-11-15 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2020081588A1 (en) | 2018-10-17 | 2020-04-23 | Dana-Farber Cancer Institute, Inc. | Swi/snf family chromatin remodeling complexes and uses thereof |
| EP3917517A4 (en) | 2019-01-29 | 2023-01-25 | Foghorn Therapeutics Inc. | CONNECTIONS AND USES THEREOF |
| US12509453B2 (en) | 2019-01-29 | 2025-12-30 | Foghorn Therapeutics Inc. | BRM/BRG1 inhibitors and uses thereof |
| US12384776B2 (en) | 2019-01-29 | 2025-08-12 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| AU2021213811A1 (en) | 2020-01-29 | 2022-07-28 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| CN115484948A (zh) * | 2020-01-29 | 2022-12-16 | 福宏治疗公司 | 化合物及其用途 |
| US12383555B2 (en) | 2020-05-20 | 2025-08-12 | Foghorn Therapeutics Inc. | Methods of treating cancers |
| EP4153176A4 (en) * | 2020-05-20 | 2024-05-29 | Foghorn Therapeutics Inc. | METHODS OF TREATING CANCER |
| AU2021359129A1 (en) * | 2020-10-16 | 2023-06-01 | Proxygen Gmbh | Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof |
| US12606553B2 (en) | 2021-03-09 | 2026-04-21 | Foghorn Therapeutics Inc. | Crystalline forms, compositions containing same, and methods of their use |
| CN117337179A (zh) * | 2021-03-19 | 2024-01-02 | 福宏治疗公司 | Brg1和brm的酶活性抑制剂的治疗方案 |
| US20250339441A1 (en) * | 2022-04-08 | 2025-11-06 | Foghorn Therapeutics Inc. | Methods of treating cancer |
| WO2024099440A1 (zh) * | 2022-11-11 | 2024-05-16 | 苏州信诺维医药科技股份有限公司 | 一种稠环化合物、其用途及含其的药物组合物 |
| WO2025082531A1 (en) * | 2023-10-20 | 2025-04-24 | Suzhou Zanrong Pharma Limited | Compounds and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005261487A1 (en) * | 2004-07-12 | 2006-01-19 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Amide derivatives as inhibitors of histone deacetylase |
| EP2349484A2 (en) * | 2008-07-15 | 2011-08-03 | Novartis AG | Heteroaryl derivatives as dgat1 inhibitors |
| EP2655330B1 (en) * | 2010-12-22 | 2016-02-10 | Purdue Pharma LP | Substituted pyridines as sodium channel blockers |
| EP3119775B1 (en) * | 2014-03-18 | 2019-11-06 | F. Hoffmann-La Roche AG | Oxepan-2-yl-pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use |
| MA41598A (fr) * | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
| WO2018187614A1 (en) * | 2017-04-05 | 2018-10-11 | Foghorn Therapeutics | Compounds and uses thereof |
| WO2018213422A1 (en) * | 2017-05-17 | 2018-11-22 | Foghorn Therapeutics | Compounds and uses thereof |
| US11497752B2 (en) | 2018-01-30 | 2022-11-15 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| JP2022508155A (ja) * | 2018-11-21 | 2022-01-19 | フォグホーン セラピューティクス インコーポレイテッド | がんを治療する方法 |
| SG11202106444WA (en) * | 2018-12-19 | 2021-07-29 | Leo Pharma As | Amino-acid anilides as small molecule modulators of il-17 |
| EA202192101A1 (ru) * | 2019-11-21 | 2021-12-09 | Фогхорн Терапьютикс Инк. | Соединения и их применение |
| JP7693688B2 (ja) | 2020-01-29 | 2025-06-17 | フォグホーン セラピューティクス インコーポレイテッド | 化合物およびその使用 |
-
2020
- 2020-01-29 CN CN202080025628.0A patent/CN113645971B/zh active Active
- 2020-01-29 AU AU2020214308A patent/AU2020214308A1/en not_active Abandoned
- 2020-01-29 ES ES20749261T patent/ES3032327T3/es active Active
- 2020-01-29 US US17/425,140 patent/US20230079819A1/en active Pending
- 2020-01-29 EP EP20749261.2A patent/EP3917527B1/en active Active
- 2020-01-29 WO PCT/US2020/015723 patent/WO2020160180A1/en not_active Ceased
- 2020-01-29 IL IL285177A patent/IL285177B2/en unknown
- 2020-01-29 JP JP2021544152A patent/JP7665518B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022523074A5 (enExample) | ||
| Petroni et al. | Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment | |
| JP4729503B2 (ja) | 抗癌剤の奏効率増強剤 | |
| JP2023512038A5 (enExample) | ||
| JP6706255B2 (ja) | 放射線、酸化セリウムナノ粒子、及び化学療法剤の併用によるがんの治療 | |
| JP2024529976A5 (enExample) | ||
| JP2008501630A6 (ja) | 抗癌剤の効果増強剤 | |
| JP2020158507A6 (ja) | 放射線、酸化セリウムナノ粒子、及び化学療法剤の併用によるがんの治療 | |
| Liu et al. | The role of autophagy in the resistance to BRAF inhibition in BRAF-mutated melanoma | |
| WO2019072220A1 (zh) | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 | |
| Kelly et al. | Chemotherapy in metastatic colorectal cancer | |
| CN101332301A (zh) | 一种抗肿瘤组合物及其应用 | |
| AU2026200456A1 (en) | Treatment of canine cancers | |
| CN108434455A (zh) | Mthfd2特异性抑制剂在防治结直肠癌方面的应用 | |
| CN112566628A (zh) | 预防和治疗癌症的药物组合物，包括棉酚、苯乙双胍和抗癌剂 | |
| ES3030540T3 (en) | Treatment of breast cancer using combination therapies comprising gdc-9545 and gdc-0077 | |
| ES2389809T3 (es) | Terapias anticancerosas | |
| BR112020026382A2 (pt) | combinações de poziotinibe com um anticorpo anti-her1, her2 ou her4 e métodos de uso das mesmas | |
| Irusta | Roads to the strategic targeting of ovarian cancer treatment | |
| JP2021530504A5 (enExample) | ||
| IL307965A (en) | compounds and their uses | |
| Al-Muswie et al. | Colon Cancer: Risk Factors and Therapeutic Approaches | |
| CN115397422A (zh) | 包含利匹韦林的组合物和其用于治疗肿瘤或癌症的用途 | |
| US20170202965A1 (en) | Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent | |
| CN118717798A (zh) | 一种提高肿瘤化疗效果的药物及氢分子在制备用于提高肿瘤化疗效果药物中的应用 |